Luke Wharton

4004 Wesbrook Mall
Vancouver, BC V6T2A3, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals.

Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals.

Journal: Inorganic chemistry

Published: June 22, 2026

Challenging the Macrocycle Paradigm: Four-Arm, High-Denticity Acyclic Chelators for Radiopharmaceuticals Incorporating Actinium and Lanthanides.

Challenging the Macrocycle Paradigm: Four-Arm, High-Denticity Acyclic Chelators for Radiopharmaceuticals Incorporating Actinium and Lanthanides.

Journal: Inorganic chemistry

Published: March 17, 2026

Carboxylic- and Amide Donor-Functionalized Pyridine-N-trans-Substituted Cyclen-Based Chelators for 203Pb/212Pb Theranostic Radiopharmaceuticals.

Carboxylic- and Amide Donor-Functionalized Pyridine-N-trans-Substituted Cyclen-Based Chelators for 203Pb/212Pb Theranostic Radiopharmaceuticals.

Journal: Inorganic chemistry

Published: October 25, 2025

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Journal: ACS bio & med chem Au

Published: October 02, 2025

Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates.

Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates.

Journal: Journal of inorganic biochemistry

Published: July 02, 2025

Chelating [227Th]Th4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.

Chelating [227Th]Th4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.

Journal: Bioconjugate chemistry

Published: May 10, 2025

Novel direct alpha spectroscopy technique for225Ac radiopharmaceutical detection in cancer cells.

Novel direct alpha spectroscopy technique for225Ac radiopharmaceutical detection in cancer cells.

Journal: Physics in medicine and biology

Published: January 16, 2025

The H2Sxmacropa Series: Increasing the Chemical Softness of H2macropa with Sulfur Atoms to Chelate Radiometals [213Bi]Bi3+ and [203Pb]Pb2+ for Radiopharmaceutical Applications.

The H2Sxmacropa Series: Increasing the Chemical Softness of H2macropa with Sulfur Atoms to Chelate Radiometals [213Bi]Bi3+ and [203Pb]Pb2+ for Radiopharmaceutical Applications.

Journal: Inorganic chemistry

Published: October 22, 2024

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 02, 2024

In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept.

In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept.

Journal: Physics in medicine and biology

Published: April 24, 2024

Quantitative SPECT imaging of 155Tb and 161Tb for preclinical theranostic radiopharmaceutical development.

Quantitative SPECT imaging of 155Tb and 161Tb for preclinical theranostic radiopharmaceutical development.

Journal: EJNMMI physics

Published: April 22, 2024

Preclinical evaluation of [225Ac]Ac-crown-TATE - An alpha-emitting radiopharmaceutical for neuroendocrine tumors.

Preclinical evaluation of [225Ac]Ac-crown-TATE - An alpha-emitting radiopharmaceutical for neuroendocrine tumors.

Journal: Nuclear medicine and biology

Published: April 08, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026